The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

http://www.wikidata.org/entity/Q39136811

about

Parkin Regulation and Neurodegenerative Disorders Multifunctional Abl kinases in health and disease Protein Kinases and Parkinson's Disease c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders Defying c-Abl signaling circuits through small allosteric compounds.LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.Therapeutic strategies in Parkinson's disease: what we have learned from animal models.Active immunization therapies for Parkinson's disease and multiple system atrophy.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.Neuroprotective Effects of Loganin on MPTP-Induced Parkinson's Disease Mice: Neurochemistry, Glial Reaction and Autophagy Studies.Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.Nilotinib - Differentiating the Hope from the Hype.Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia.The c-Abl inhibitor in Parkinson disease.Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced mitochondrial fragmentation and neuronal cell death.Biological and Clinical Implications of Comorbidities in Parkinson's Disease.α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential.Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review).Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System.Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives.The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease

P2860

Q26770443-CA432899-6BB8-4997-AE07-417247CA30CB Q26771277-24B97627-9770-40B9-80C9-ED8CFA700509 Q28067636-BDC36B0B-CC11-4ACB-8B36-EFA0DD702D8C Q28070292-561FEDB6-ADFB-4A86-B47E-D677F254BA57 Q28075692-935B148F-3BF8-4080-8D58-DBA3AA5B6BB4 Q29048615-D2059489-18BF-4519-B472-CFDC91EEC329 Q30009269-DEDA209B-C5C4-46CC-8EE9-3E05A4BFD2A6 Q35898177-66730DA9-CA20-4561-8459-9971627932B2 Q37004163-68DDB653-A635-4975-A027-9595BE84E7BF Q37137895-1D5F6D08-ECA0-4644-85E9-F335A420807F Q37225128-A3E14772-9D47-4D87-A2C6-1F25B33568CA Q37354028-EA04B1AA-880B-42ED-A723-11E390B33F7E Q38290759-9E578C96-D586-49FE-AF52-9B4FD7FE84EF Q38564102-A3B05284-50FB-4822-991D-1F13C1DC07F8 Q38658203-2D2A22AE-00A1-4BD1-A6F9-FA978B9E1882 Q38726985-58E82C6C-47A8-45F1-AFDA-4C6FF5C5A555 Q38740508-9ECF011F-6311-44A9-BBC0-688C0C6CE2FB Q38766966-2A56118C-702B-4074-935A-8001919EA4E4 Q38840128-F5CFF4E4-FA23-459E-AB7B-1DFD83A5E496 Q38988911-B69DCFB1-A57E-4403-879A-A4190F41AEAA Q39081447-2AA92798-8382-479B-9BD0-790D011231DD Q39264622-A18B07C7-2113-44A9-B452-4873E8672D0E Q41015843-BAD07D03-7FEC-49FE-9DE4-110F0343B746 Q41646475-0364E66D-F289-464D-8DD5-8CD494298B1C Q47124745-803526CE-F389-43C6-B31B-67197BC0F84F Q47133507-221DF530-F890-49CB-AB89-2E70DD104A68 Q47137783-A1BBC209-3159-4523-873A-A4E4C6C4AC9F Q47193560-6CD1DADF-7E20-44E1-BFA0-CD3BD68062AA Q48274208-7AE30445-AD48-4F6D-8656-11917C1F0994 Q48547723-AA1ECE6B-E921-445B-9824-A1CBE457DD85 Q48829255-86AF9131-02F8-48AF-8B80-2F3B73A4A7CC Q49568112-6E4A035A-32B7-438B-8D29-31B96BFA9850 Q50648904-6059438C-0EB5-4E2C-99C7-D45B52E1A46C Q52332617-8D3157CE-C914-447D-B0E2-5F2DE818CF98 Q55401120-BEF74F46-A799-4B4E-B54F-34C2D972A52C Q56567928-EF6ED5BD-EAB1-471A-90BD-09023A5F4893

P2860

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

http://www.wikidata.org/entity/Q39136811

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@en

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@nl

type

label

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@en

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@nl

prefLabel

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@en

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@nl

P1433

Q39136811-37CDC664-70A0-430D-AACC-13AAC404E3BC

P1476

Q39136811-59265BD3-7706-42FD-9858-C3841D47DFE1

P2093

Q39136811-1ACF3584-3DA0-4500-AEC2-1F22D3C52006

Q39136811-4A7B393B-94D2-49AE-879D-E12D365896E9

Q39136811-9236CCD1-3734-4129-8019-2064814A641B

Q39136811-9ED253FE-FE37-4796-B339-0DCE1B2A72AF

P2860

Q39136811-024BA598-96F6-4592-AB31-FF6C7FC8023F

Q39136811-1CC7DAFF-AB52-4E35-B7FA-D7C4E70EF9D4

Q39136811-251F3312-9F27-42ED-A8B1-160BD9599E6A

Q39136811-272A7A20-668C-43CD-A30A-D6E8A81F33BF

Q39136811-36CE5C64-C187-46D5-B1CD-3F29A735B057

Q39136811-3F9996F3-ACFD-433E-A27D-82A5C468EBF4

Q39136811-448A38EA-E8E7-4896-8383-8448C73BACA7

Q39136811-44D6C4A0-C647-4B92-AE4E-404C00083A6D

Q39136811-4623E977-9ACA-468B-B0BE-DE562A119DE6

Q39136811-6EE9B769-82D6-43B0-B7BF-BCF5C59A03A3

P2888

Q39136811-C5EED170-5FC9-4AFC-A14C-2DAA304A61F8

P304

Q39136811-8060AD6E-0BCF-4AE8-A146-900E9DCDB1AE

P31

Q39136811-5C04979E-C4A0-4FF0-8436-8360123419A6

P356

Q39136811-9C950CD6-F3E5-4816-AEF9-71CCD329793B

P407

Q39136811-33E6D923-8C87-4224-AC2C-2D5217AD7890

P478

Q39136811-10F48ECC-E57F-4345-A051-4A43639E21AB

P50

Q39136811-7F0DD83D-C6C5-494A-B28F-F8992446FBDE

Q39136811-B57F991F-1E09-4F7B-BE9B-BE44495D9AE3

P577

Q39136811-B6BA5F37-1619-4AD5-9F3A-C94756227960

P5875

Q39136811-46992848-071F-436A-98BA-24E01501D78F

P698

Q39136811-F772C4CC-F7D0-4C1C-944E-07CF133E041C

P921

Q39136811-68005CD6-F5A8-4A35-8B98-9916FCDA4C52

Q39136811-9D3CEACF-A253-4FF3-AB7C-E758695379A3

P932

Q39136811-2D61A284-71E0-4E91-AEC1-6B542907CA68

P356

P1433

Scientific Reports

P1476

The c-Abl inhibitor, nilotinib ...... model of Parkinson's disease.

@en

P2093

Han Seok Ko

http://www.w3.org/2001/XMLSchema#string

Saurav Brahmachari

http://www.w3.org/2001/XMLSchema#string

Senthilkumar S Karuppagounder

http://www.w3.org/2001/XMLSchema#string

Valina L Dawson

http://www.w3.org/2001/XMLSchema#string

P2860

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease

Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation

Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species

Molecular pathways of neurodegeneration in Parkinson's disease

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice

Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.

Oxidative stress and genetics in the pathogenesis of Parkinson's disease.

P2888

P304

4874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP04874

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262017897

http://www.w3.org/2001/XMLSchema#string

P698

24786396

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4007078

http://www.w3.org/2001/XMLSchema#string